VacPath SIGNED
Novel vaccine vectors to resist pathogen challenge
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0VacPath project word cloud
Explore the words cloud of the VacPath project. It provides you a very rough idea of what is the project "VacPath" about.
Project "VacPath" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT UTRECHT
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 2˙701˙874 € |
| EC max contribution | 2˙701˙874 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2018 |
| Funding Scheme | MSCA-ITN-ETN |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-01-01 to 2022-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITEIT UTRECHT | NL (UTRECHT) | coordinator | 531˙239.00 |
| 2 | UNIVERSITAT BASEL | CH (BASEL) | participant | 562˙553.00 |
| 3 | HEINRICH-HEINE-UNIVERSITAET DUESSELDORF | DE (DUSSELDORF) | participant | 505˙576.00 |
| 4 | STATENS SERUM INSTITUT | DK (KOBENHAVN S) | participant | 297˙522.00 |
| 5 | ABERA BIOSCIENCE AB | SE (STOCKHOLM) | participant | 281˙982.00 |
| 6 | MICROBIOTEC SRL | IT (MONTERIGGIONI) | participant | 261˙499.00 |
| 7 | UNIVERSITA DEGLI STUDI DI SIENA | IT (SIENA) | participant | 261˙499.00 |
| 8 | SCLAVO VACCINES ASSOCIATION | IT (SIENA) | partner | 0.00 |
Map
Project objective
Infectious diseases are a major burden and constant threat to European populations and economies. While barely perceived as a danger not too long ago, a combination of potential rapid spread of novel pathogens across the globe, antibiotics resistance, a come-back of “old” pathogens and persistence of yet to be combated pathogens has raised the demand for effective but safe vaccines. An example of a yet to be combated pathogen is the obligate intracellular bacterium Chlamydia trachomatis. This pathogen is the major cause of sexually transmitted bacterial disease in humans, and poses a world-wide health concern. While responsive to antibiotics, re-infections frequently occur, urging the need for a prophylactic vaccine. Nevertheless, insufficient knowledge on how to vaccinate against intracellular pathogens hampers the development of such vaccines. In the proposed project, 5 academic and 2 private partners will cooperate to educate early stage researchers (ESR) in the diverse aspects of novel vaccine development. ESR will design and construct innovative and safe virus-, bacterium-, and plasmid-based vaccine vectors that induce both cell-mediated and humoral immunity, to control infections with intracellular pathogens. They will test these vaccines and improve their efficacy in preclinical models of C. trachomatis infection, and unravel the cellular and molecular mechanisms underlying the induction of protective immune responses, to uncover possibilities for general vaccine vector optimisation. The end-result will be a new generation of safe vaccine vectors that can be exploited to vaccinate against C. trachomatis, and can be adapted to vaccinate against further intracellular pathogens of choice. Moreover, this project will educate a new generation of scientists that, through the offered, integrated training, will be ready to enter the European task force, in academia or industry, to find creative solutions to future pathogen-imposed challenges.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACPATH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VACPATH" are provided by the European Opendata Portal: CORDIS opendata.